CLINICAL TRIALS PROFILE FOR DILANTIN
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Dilantin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00005951 ↗ | Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | Completed | National Cancer Institute (NCI) | Phase 1 | 2000-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma. |
| NCT00005951 ↗ | Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | Completed | Duke University | Phase 1 | 2000-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma. |
| NCT00040469 ↗ | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | Terminated | Center for Cell and Gene Therapy, Baylor College of Medicine | Phase 2 | 2000-08-01 | The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years. |
| NCT00040469 ↗ | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | Terminated | Texas Children's Hospital | Phase 2 | 2000-08-01 | The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years. |
| NCT00040469 ↗ | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | Terminated | The Methodist Hospital Research Institute | Phase 2 | 2000-08-01 | The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years. |
| NCT00040469 ↗ | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | Terminated | The Methodist Hospital System | Phase 2 | 2000-08-01 | The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Dilantin
Condition Name
Clinical Trial Locations for Dilantin
Trials by Country
Clinical Trial Progress for Dilantin
Clinical Trial Phase
Clinical Trial Sponsors for Dilantin
Sponsor Name
